Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitisA phase 2b randomized study.

[1]  A. Armstrong,et al.  Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2 , 2020, The Journal of dermatological treatment.

[2]  D. Margolis,et al.  Pain is a common and burdensome symptom of atopic dermatitis in United States adults. , 2019, The journal of allergy and clinical immunology. In practice.

[3]  D. Margolis,et al.  Validation and interpretation of short form 12 and comparison with dermatology life quality index in atopic dermatitis in adults. , 2019, The Journal of investigative dermatology.

[4]  J. Silverberg,et al.  Depression and psychological distress in US adults with atopic dermatitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  J. Silverberg,et al.  Conceptual Model to Illustrate the Symptom Experience and Humanistic Burden Associated With Atopic Dermatitis in Adults and Adolescents , 2019, Dermatitis : contact, atopic, occupational, drug.

[6]  D. Margolis,et al.  Health Utility Scores of Atopic Dermatitis in US Adults. , 2019, The journal of allergy and clinical immunology. In practice.

[7]  D. Margolis,et al.  Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults , 2019, The British journal of dermatology.

[8]  J. Silverberg,et al.  Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis. , 2019, Journal of the American Academy of Dermatology.

[9]  J. Silverberg,et al.  Treatment of atopic dermatitis with tralokinumab, an anti–IL‐13 mAb , 2019, The Journal of allergy and clinical immunology.

[10]  J. Silverberg,et al.  A Comprehensive Conceptual Model of the Experience of Chronic Itch in Adults , 2018, American Journal of Clinical Dermatology.

[11]  D. Margolis,et al.  Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  C. Flohr,et al.  Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE) , 2018, Journal of the American Academy of Dermatology.

[13]  J. Silverberg,et al.  Burden of skin pain in atopic dermatitis. , 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  J. Gelfand,et al.  Impact of atopic dermatitis on health‐related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey , 2017, Journal of the American Academy of Dermatology.

[15]  J. Silverberg,et al.  The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis. , 2017, Dermatologic clinics.

[16]  C. Akdis,et al.  Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. , 2016, The Journal of allergy and clinical immunology.

[17]  J. Silverberg,et al.  Burden of Sleep and Fatigue in US Adults With Atopic Dermatitis , 2016, Dermatitis : contact, atopic, occupational, drug.

[18]  J. Silverberg,et al.  Association between Atopic Dermatitis and Depression in US Adults. , 2015, The Journal of investigative dermatology.

[19]  Kathryn A. Lee,et al.  Cytokine polymorphisms and plasma levels are associated with sleep onset insomnia in adults living with HIV/AIDS , 2015, Brain, Behavior, and Immunity.

[20]  S. Nutten.  Atopic Dermatitis: Global Epidemiology and Risk Factors , 2015, Annals of Nutrition and Metabolism.

[21]  A. Finlay,et al.  Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data , 2015, Dermatology.

[22]  L. Misery,et al.  The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries , 2014, The Journal of investigative dermatology.

[23]  H. Williams,et al.  Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting , 2012, Allergy.

[24]  S. Takeuchi,et al.  Visual analogue scale: evaluation of the instrument for the assessment of pruritus. , 2012, Acta dermato-venereologica.

[25]  M. Augustin,et al.  Quality of Life Measures for Dermatology: Definition, Evaluation, and Interpretation , 2012, Current Dermatology Reports.

[26]  A. Finlay,et al.  Translating the science of quality of life into practice: What do dermatology life quality index scores mean? , 2005, The Journal of investigative dermatology.

[27]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[28]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[29]  J. Silverberg,et al.  Sleep Disturbance and Sleep-Related Impairment in Adults With Atopic Dermatitis: A Cross-sectional Study. , 2018, Dermatitis : contact, atopic, occupational, drug.

[30]  Erika Sevetson,et al.  The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.